Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
$5.84
-1.3%
$5.97
$2.41
$7.57
$454.53M2.541.79 million shs234,025 shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$17.92
+1.2%
$17.56
$10.41
$138.81
$1.75B0.496.31 million shs1.13 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-5.13%+8.82%+3.68%+25.42%-21.49%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-2.96%-4.32%-2.96%+3.57%-85.78%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
$5.84
-1.3%
$5.97
$2.41
$7.57
$454.53M2.541.79 million shs234,025 shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$17.92
+1.2%
$17.56
$10.41
$138.81
$1.75B0.496.31 million shs1.13 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-5.13%+8.82%+3.68%+25.42%-21.49%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-2.96%-4.32%-2.96%+3.57%-85.78%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
3.09
Buy$15.00156.72% Upside
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
2.10
Hold$39.32119.37% Upside

Current Analyst Ratings Breakdown

Latest SLDB and SRPT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/22/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeMarket PerformOutperform$50.00
9/15/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$22.00
9/9/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetMarket Perform$12.00 ➝ $15.00
8/25/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell
8/20/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetUnderperform$17.00
8/15/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetSell$12.00
8/14/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$15.00
8/14/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$15.00 ➝ $13.00
8/13/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$17.00 ➝ $14.00
8/7/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$19.00
8/7/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$48.00 ➝ $50.00
(Data available from 9/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
$8.09M56.24N/AN/A$3.43 per share1.70
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$1.90B0.92$2.39 per share7.50$15.99 per share1.12
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$124.70M-$2.80N/AN/AN/AN/A-69.70%-56.74%11/5/2025 (Estimated)
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$235.24M-$0.87N/A1.64N/A-2.34%-1.03%-0.37%11/5/2025 (Estimated)

Latest SLDB and SRPT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$0.51-$0.42+$0.09-$0.42N/AN/A
8/6/2025Q2 2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$0.89$2.02+$1.13$1.89$530.66 million$611.09 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/AN/AN/AN/AN/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/A
9.34
9.34
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
0.84
2.89
1.81

Institutional Ownership

CompanyInstitutional Ownership
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
81.46%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
86.68%

Insider Ownership

CompanyInsider Ownership
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
1.90%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
7.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
10077.87 million76.39 millionOptionable
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
1,37297.71 million90.29 millionOptionable

Recent News About These Companies

Cantor Fitzgerald Keeps Their Hold Rating on Sarepta Therapeutics (SRPT)
Sarepta Therapeutics (SRPT) Receives a Hold from Evercore ISI
Sarepta Therapeutics (NASDAQ:SRPT) Raised to Outperform at BMO Capital Markets
BMO upgrades Sarepta on Elevidys uptake, pipeline prospects
BMO Capital Upgrades Sarepta Therapeutics (SRPT)
Sarepta Therapeutics' (SRPT) "Buy" Rating Reiterated at Guggenheim
Q3 EPS Forecast for Sarepta Therapeutics Raised by Analyst

New MarketBeat Followers Over Time

Media Sentiment Over Time

Solid Biosciences stock logo

Solid Biosciences NASDAQ:SLDB

$5.84 -0.08 (-1.30%)
As of 11:57 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Sarepta Therapeutics stock logo

Sarepta Therapeutics NASDAQ:SRPT

$17.92 +0.20 (+1.15%)
As of 11:57 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.